C609T polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin | Zendy

Misato Nagata | Zendy; Tatsuo Kimura | Zendy; Tomohiro Suzumura | Zendy; Yukimi Kira | Zendy; Toshiyuki Nakai | Zendy; Kanako Umekawa | Zendy; Hidenori Tanaka | Zendy; Kuniomi Matsuura | Zendy; Shigeki Mitsuoka | Zendy; Naruo Yoshimura | Zendy; Takako Oka | Zendy; Shinzoh Kudoh | Zendy; Kazuto Hirata | Zendy

Open Access

C609T polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin

Author(s) -

Misato Nagata,

Tatsuo Kimura,

Tomohiro Suzumura,

Yukimi Kira,

Toshiyuki Nakai,

Kanako Umekawa,

Hidenori Tanaka,

Kuniomi Matsuura,

Shigeki Mitsuoka,

Naruo Yoshimura,

Takako Oka,

Shinzoh Kudoh,

Kazuto Hirata

Publication year - 2013

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s10839

Subject(s) - genotype , medicine , pharmacokinetics , lung cancer , pharmacology , chemistry , gastroenterology , oncology , endocrinology , gene , biochemistry

Amrubicin hydrochloride (AMR) is a key agent for lung cancer. NADPH quinone oxidoreductase 1 (NQO1) metabolizes the quinone structures contained in both amrubicin (AMR) and amrubicinol (AMR-OH). We hypothesized that NQO1 C609T polymorphism may affect AMR-related pharmacokinetics and clinical outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research